This CME program is derived from content presented at the Florida Society of Neurology 2019 held in Orlando, Florida on September 13, 2019. The expert faculty will discuss the importance of patient screening, accurate diagnosing, and cross-disciplinary approaches for the management of Hereditary Transthyretin-Mediated Amyloidosis (hATTR). This includes a review the most recent clinical trial data for the treatment of polyneuropathy of hATTR. The information provided by the expert faculty will enable healthcare providers to optimally treat and manage their patients with Hereditary Transthyretin-Mediated Amyloidosis.
Advances in the Diagnosis and Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
- Understand the importance of patient screening, accurate diagnosing, and cross-disciplinary approaches for the management of hATTR.
- Analyze the most recent clinical trial data for the treatment of polyneuropathy of hATTR.
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Sami Khella, MD||Consultant/Advisor: Akcea Therapeutics, Alnylum Pharmaceuticals, Eidos Therapeutics, Pfizer|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from Akcea Therapeutics.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Akcea Therapeutics do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].